US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

20.30 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
What's Next: Amneal Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report Third Quarter 2024 Results on November 8, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
News headline image
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
News headline image
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amneal Reports Second Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal to Report Second Quarter 2024 Results on August 9, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amneal Releases 2023 Environmental, Social and Governance Report
From Amneal Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks ↗
Here are three stocks to buy up 100% in the past year. Make sure you add these to your portfolio so that you can reap the benefits. 
Via InvestorPlace
News headline image
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >